Two key things in this preso and forget the rest:
1. tie-up with global medical device distributors at the 'decision maker' stage.
2. re-domiciling to the US by 2017.
Make or break - if this comes off, this will re-rate hard. If not, then you are relying on funding a global marketing strategy using deeply discounted cap raisings. Otherwise known as a road to nowhere fast!
Ann: Investor presentation, page-8
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
